Stroke severity — not prior clot-busting drugs — determines who benefits from endovascular therapy in distal vessel strokes

When it comes to treating strokes caused by blockages in smaller, more distal brain vessels, a new analysis suggests that the decision to use endovascular therapy (EVT) should hinge on how severe the stroke is — not on whether the patient already received IV thrombolysis (IVT, or clot-busting drugs). The findings come from a secondary analysis of the DISTAL randomized trial, presented at the World Stroke Congress 2026 in Seoul.

The analysis focused on 319 DISTAL patients with non-minor strokes (baseline NIHSS > 5). Overall, prior IVT use did not significantly change how well EVT worked. But among patients who were ineligible for IVT, stroke severity at admission made a big difference — EVT's benefit grew stronger as severity increased, particularly in patients with an NIHSS score above 10.

Key Takeaways:

• Prior IVT status did not significantly modify EVT's functional benefit in non-minor distal vessel strokes
• Among IVT-ineligible patients, EVT benefit was strongly tied to baseline NIHSS, with clearest gains above a score of 10
• Both DISTAL and the companion ESCAPE-MeVO trial found no overall benefit of EVT over medical management in distal occlusions, tempering enthusiasm for routine use

Why it matters: These findings push back against a one-size-fits-all approach to EVT in distal vessel strokes. Clinicians may need to apply a higher severity threshold — rather than vessel location alone — when deciding whether to pursue endovascular intervention in this challenging patient population.